Levetiracetam in absence epilepsy

Developmental Medicine and Child Neurology

Volumn 50, Issue 11, 2008, Pages 850-853

  Verrotti, Alberto ^a   Cerminara, Caterina ^b   Domizio, Sergio ^a   Mohn, Angelika ^a   Franzoni, Emilio ^c   Coppola, Giangennaro ^d   Zamponi, Nelia ^e   Parisi, Pasquale ^f   Iannetti, Paola ^f   Curatolo, Paolo ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Salesi Children's Hospital   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM;

ABSENCE; ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CHILD CARE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EEG ABNORMALITY; ELECTROCARDIOGRAPHY MONITORING; EVENING DOSAGE; FEMALE; HUMAN; IRRITABILITY; ITALY; LABORATORY TEST; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHYSICAL DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; VITAL SIGN;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; EPILEPSY, ABSENCE; FEMALE; HUMANS; MALE; PIRACETAM; PROSPECTIVE STUDIES;

EID: 54249129318     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2008.03099.x     Document Type: Article

References (34)

1. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsy and epileptic syndromes. Epilepsia 1989; 30: 389-99.
2. Engel J; International League Against Epilepsy. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: Report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42: 796-803.
3. Dieterich E, Baier WK, Doose H, Tuxhorn I. Long term follow-up of childhood epilepsy with absences at onset. Neuropediatrics 1985; 16: 149-54.
4. Siren A, Kylliainen A, Tenhunen M, et al. Beneficial effects of antiepileptic medication on absence seizures and cognitive functioning in children. Epilepsy Behav 2007; 11: 85-91.
5. Coppola G, Auricchio G, Federico F, et al. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: An open-label, randomized, parallel-group study. Epilepsia 2004; 45: 1049-53.
6. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther 2007; 113: 165-83.
7. Posner EB, Mohamed K, Marson AG. A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure 2005; 14: 117-22.
8. Isojarvi JL, Tauboll E, Tapainem JS, Pakarinem AJ, Laatikainem TJ, Knip M. On the association between valproate and polycystic ovary syndrome: A response and an alternative view. Epilepsia 2001; 42: 305-10.
9. Verrotti A, Greco R, Latini G, Chiarelli F. Endocrine and metabolic changes in epileptic patients receiving valproic acid. J Pediatr Endocrinol Metab 2005; 18: 423-30.
10. Di Bonaventura C, Fattouch J, Mari F, et al. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord 2005; 7: 231-35.
11. Andermann E, Andermann F, Meyvish P, Tonner F. Efficacy and tolerability Levetiracetam add-on therapy in patients with refractory idiopathic generalised epilepsy. Epilepsia 2006; 47: 187.
12. Labate A, Colosimo E, Gambardella A, Leggio U, Ambrosio R, Quattrone A. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: An open label study. Seizure 2006; 15: 214-18.
13. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Levetiracetam monotherapy study group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-08.
14. Verrotti A, Cerminara C, Coppola G, et al. Levetiracetam in juvenile myoclonic epilepsy: Long term in newly diagnosed adolescents. Dev Med Child Neurol 50: 29-32.
15. Glauser TA, Ayala R, Elterman RD. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia 2007; 48: 1117-22.
16. Pinto A, Sander JW. Levetiracetam: A new therapeutic option for refractory epilepsy. Int J Clin Pract 2003; 57: 616-21.
17. Klitgoord H, Pitkanen A. Antiepileptogenesis, neuroprotection and disease modification in the treatment of epilepsy: Focus on levetiracetam. Epileptic Disord 2003; 5: 59-61.
18. Noyer M, Gillard M, Matagne A. The noval antiepileptic drug levetiratacetam (UCB LO59) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995; 286: 137-46.
19. Rigo JM, Hans G, Nguyer L. The antiepileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136: 659-72.
20. 2+ currents. Seizure 2001; 10: 279-86.
21. Lynch BA, Lamberg N, Nocka K, et al. The synaptic vesicle protein SV2A in the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 101: 9861-66.
22. Carunchio I, Pieri M, Ciotti MT, Albo F, Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia 2007; 48: 654-62.
23. Polack PO, Guillemain I, Hu E, et al. Deep layer somatosensory cortical neurons initiate spike-and-wave discharges in a genetic model of absence seizures. J Neurosci 2007; 27: 6590-99.
24. D'Arcangelo G, D'Antuono M, Tancredi V, Avoli M. Neocortical hyperexcitability in a genetic model of absence seizures and its reduction by levetiracetam. Epilepsia 2006; 47: 1144-52.
25. Marrosu F, Bortolato M, Frau R, et al. Levetiracetam attenuates spontaneous spike-and-wave discharges in DBA/2J mice. Epilepsy Res 2007; 75: 224-27.
26. Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: An open-label trial. Epilepsia 2002; 43: 518-24.
27. Glauser TA, Dulac O. Preliminary efficacy of levetiracetam in children. Epileptic Disord 2003; 5 (Suppl. 1): S45-50.
28. Herranz JL. Levetiracetam in children and adolescents with epilepsy. Rev Neurol 2003; 37: 558-60.
29. Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004; 13: 55-57.
30. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology 2003; 63: 704-06.
31. Morrell MJ, Leppik I, French J, et al. The Keeper trial: Levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003; 54: 153-61.
32. Mohanraj R, Parker G, Stephen L, Brodie M. Levetiracetam in refractory epilepsy: A prospective observational study. Seizure 2005; 14: 23-27.
33. Tsai JJ, Yen DJ, MO-Song Hsih, et al. Efficacy and safety or levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: A multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 2006; 47: 72-81.
34. Patsalos PN. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics. Pharmacol Ther 2000; 85: 77-85.